Reported Earlier, Zenas Biopharm Announced The Presentation Of Additional Positive Data From The Phase 3 Indigo Trial Evaluating Obexelimab In Immunoglobulin G4-related Disease (Igg4-rd) At The European Alliance Of Associations For Rheumatology (E...

Zenas BioPharma

Zenas BioPharma

ZBIO

0.00
Reported Earlier, Zenas Biopharm Announced The Presentation Of Additional Positive Data From The Phase 3 Indigo Trial Evaluating Obexelimab In Immunoglobulin G4-related Disease (Igg4-rd) At The European Alliance Of Associations For Rheumatology (Eular) 2026 Congress In London, England
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.